Interim report May-January 2019/20
Outlook maintained for the full-year – soft quarter
We delivered an improved EBITA margin supported by good sales in Neuro and Oncology Informatics as well as by our cost reduction program. However, the third quarter was disappointing from an order perspective as the U.S. business did not live up to our expectations. Our order pipeline of Elekta Unity is strong, which ensures that the order target will be met – most likely already in the fourth quarter.
Richard HausmannPresident and CEO
Third quarter
· Gross order intake amounted to SEK 4,276 M (4,551), corresponding to an